Metraipolis › archive › dc_6023e6d2cfab
Alicaforsen — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/Alicaforsen
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-08T11:25:04.585Z
- SHA-256 of the archived text
8cc62756bcbfaa0bc12b8ff7cfe5bb5131000d395d2e6dcd2902ccb3d95c7037- Stable URL of this page
https://metraipolis.com/documento/dc_6023e6d2cfab
How to cite
Alicaforsen — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Alicaforsen (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_6023e6d2cfab (Metraipolis archive dc_6023e6d2cfab, sha256 8cc62756bcbfaa0bc12b8ff7cfe5bb5131000d395d2e6dcd2902ccb3d95c7037)
BibTeX
@misc{dc6023e6d2cfab,
title = {Alicaforsen — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/Alicaforsen},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_6023e6d2cfab; sha256 8cc62756bcbfaa0bc12b8ff7cfe5bb5131000d395d2e6dcd2902ccb3d95c7037},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Alicaforsen. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Alicaforsen (trade name Camligo) is an antisense oligonucleotide therapeutic that targets the messenger RNA for the production of human ICAM-1 receptor and is being developed for the treatment of acute disease flares in moderate to severe Inflammatory Bowel Disease (IBD). Alicaforsen inhibits ICAM-1 production, which is an important adhesion molecule involved in leukocyte migration and trafficking to the site of inflammation. Hitherto, alicaforsen has been granted orphan drug designation and is prescribed as an unlicensed medicine in accordance with international regulation, for the treatment of pouchitis and left-sided ulcerative colitis. Given the positive results from an open-label trial and one case series in patients with chronic refractory pouchitis, US FDA has agreed to a rolling submission for a license application for the treatment of pouchitis. It was discovered by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) and in 2017 Atlantic Healthcare plc took over the development for chronic antibiotic refractory pouchitis in an enema formulation. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico). Fonte: Wikipedia in inglese, voce «Alicaforsen» — https://en.wikipedia.org/wiki/Alicaforsen Wikidata Q17147922: «composto chimico» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q17147922 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Alicaforsen?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1354770020, consultata il 2026-11-08T11:20:41.672Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 0332589fc0515db03aada679fa714488625eb69276a043c441a8e6753b2e2d74